Radicava is a newly FDA-approved intravenously administered free radical scavenger for the treatment of amyotrophic lateral sclerosis (ALS). Oxidative stress has been considered to be involved in the onset and progression of ALS; it’s postulated that elimination of free radicals might protect motor neurons from oxidative stress and free radical damage in ALS patients. However, the FDA label for Radicava notes that the mechanism by which the drug exerts its therapeutic effect in patients with ALS is unknown.
If you have a Hayes login, click here to view the full report on the Knowledge Center.